about
Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cellsA Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies.Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer.The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view.RAC3 more than a nuclear receptor coactivator: a key inhibitor of senescence that is downregulated in aging.Cirrhosis, von Willebrand Factor (vWF) and the Low Incidence of Metastatic Malignancy in Injured LiverAnti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.Telomere structure and telomerase in health and disease (review).Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, ArgentinaReduction of tumor angiogenesis induced by desmopressin in a breast cancer modelExogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor CellsRacotumomab for treating lung cancer and pediatric refractory malignancies.Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours.Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells.Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies.7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies.A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation.Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA.Intermittent dietary restriction in eSS diabetic rats. Effects on metabolic control and skin morphology.Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells-Letter.
P50
Q31140123-4919C678-BADD-4078-B15D-352CE7D08F89Q33207638-1AA9FA4C-211D-4CDF-9871-0CF6A92E566EQ33346339-2BEAAC0F-A446-4599-B768-69FC0CD96090Q33445369-08900100-98D0-4E12-9B19-EB46E412A850Q33687878-999E0707-53F8-4CC0-A7BE-79D09A83D34CQ34342416-09DFA337-8321-4BDA-AAF0-725867FB0EF7Q34446327-5BDECC8C-F494-4FAE-A16C-A4DE7DAEA653Q34484061-DD3FE187-E881-4B58-B629-2D51636C75D8Q35623390-163C0D1E-C036-451A-862B-324FEAA82D09Q35636438-922EAED3-7172-4A96-A676-141149B4825FQ35967856-53028F86-F843-4F9A-B87B-B1B397C19876Q36063243-8502FD70-3EAB-4485-956C-76080297D5A4Q36246392-16FC070D-893A-4543-8CD3-545AA7E3DFA3Q36319152-CB92C504-2A5B-4166-BDDC-F1EFBBCDB2C8Q36540352-6FA4E3BF-E715-4D94-B229-702E9E3D5A9EQ36643073-6A60054D-7BA1-449C-BF72-F487229E754FQ37239002-025F8D89-BB11-4B5C-BE78-86E4F6422A5CQ37302108-9D48DB28-CAEC-4631-AF3C-EB8A7368D54DQ37483080-D988D3E0-5F71-40EE-AFB4-98356CE35606Q37611641-8CA3C6DD-A910-46BC-A8BD-76F16689C357Q38745411-1CFA6DC4-36DF-4127-9406-0BDD94AEB7EAQ38780121-9180D299-12B3-4B26-ACA1-9719AA568543Q38939866-BD1DC42B-130A-47F0-A9B0-F8A47BDDBD2CQ39000756-B4B8B6C6-0E0F-414C-856A-AA5E5C5E2DB6Q39003702-5BCB1E1A-B7EC-4509-B593-D14CF793B188Q39381625-122D0D8D-2D04-45EC-8276-E93322142C80Q39672464-C3609C20-75DE-4153-AEB1-0AAFC60FD6BBQ39750020-CBA25FD8-3FEC-46A7-9752-689AD2534A31Q39856347-F741A3A4-3657-4A90-BC86-134C15A5AD24Q40082517-A4CA5FEF-C4E4-472A-80B8-1E0D3B72282DQ40148409-041BE87D-8484-48BB-AADD-E8081675A0D8Q40525385-A7A34AEA-5FC4-42DE-A135-CA2C733DC41EQ43684989-9A9EDDA6-A1DE-484D-BFE8-4C50D34FE591Q44124448-26ECB06E-85C6-4FA1-8D5F-5A0A572D32FCQ44197472-877E1066-D6CD-4B46-A5F4-2A32FC2E2A46Q44243565-B0CE83C6-0412-442F-93F0-78711EC46888Q44967310-39E94FB2-A360-4555-A5B8-8D9D01E36A7FQ48888659-B4F6E289-A6BB-454B-BA8A-9907D21F6D1EQ51274934-FAA48769-5581-41A2-A3FF-29CA3642E0F2Q51569099-1BB70FF6-B850-4F96-9066-521B680A6CF4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel F Alonso
@ast
Daniel F Alonso
@en
Daniel F Alonso
@es
Daniel F Alonso
@nl
type
label
Daniel F Alonso
@ast
Daniel F Alonso
@en
Daniel F Alonso
@es
Daniel F Alonso
@nl
prefLabel
Daniel F Alonso
@ast
Daniel F Alonso
@en
Daniel F Alonso
@es
Daniel F Alonso
@nl
P106
P1153
7102896260
P31
P496
0000-0002-0601-613X